Oculis logo

Oculis

OCS | NASDAQ
Chart Builder DCF Calculator
$7.63
-$0.01 (-0.13%)
At close: Nov 16, 2026, 4:00 PM ET
$7.48
-$0.15 (-1.97%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.13%

Rating

Updated: Nov 16, 2026
32.2
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #741/1021 (Top 73%)

Key Statistics

Market Data

Market Cap $471.02M
1D Range
7.55 8.21
52W Range
6.83 32.65

Valuation (TTM)

PE -4.40
PB 1.74
EV/EBITDA -4.49

Valuation (NTM)

Forward PE N/A
Forward PEG 0.23
Price Target $38.00
Loading financial charts...

Profile

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the a...

Sector Healthcare
Industry Biotechnology
Employees 60
IPO Date May 18, 2021
Website oculis.com
Fiscal Year January - December

Latest News

Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals

6 months ago · marketbeat.com

Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

6 months ago · globenewswire.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki

6 months ago · globenewswire.com

Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

6 months ago · globenewswire.com

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

6 months ago · globenewswire.com

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

6 months ago · zacks.com

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Reports Q1 2026 Financial Results and Provides Company Update

6 months ago · globenewswire.com

Oculis Reports Q1 2026 Financial Results and Provides Company Update
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

6 months ago · globenewswire.com

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

7 months ago · globenewswire.com

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

7 months ago · globenewswire.com

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$0.37
Beat +21.49%
REV
$8.1K
Miss -96.89%
Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$38.00
Upside
+398.03%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.